Progyny Inc Revenue Growth Rates (PGNY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Progyny Inc   (NASDAQ: PGNY)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare
 

PGNY's Revenue Growth by Quarter and Year

Progyny Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PGNY/growth
https://api.csimarket.com/api/v1/companies/PGNY/fundamentals
https://api.csimarket.com/api/v1/companies/PGNY/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
PGNY Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 341.25
2nd Quarter June 350.51
1st Quarter March 328.07
FY 1,019.83

PGNYs Annual Revenue
Progyny Inc 's Revenue in the fiscal year 2025 $ 1,288.48 millions
Progyny Inc 's Revenue in the fiscal year 2024 $ 1,166.36 millions
Progyny Inc 's Revenue in the fiscal year 2023 $ 1,087.80 millions
Progyny Inc 's Revenue in the fiscal year 2022 $ 786.91 millions
Progyny Inc 's Revenue in the fiscal year 2021 $ 500.62 millions




PGNY Revenue third quarter 2026 Y/Y Growth Comment
Progyny Inc reported Revenue growth of 9.08% year on year in the third quarter 2026, to $ 341.25 millions, this is lower than Progyny Inc 's recent average Revenue rise of 48.75%.

Looking into third quarter 2026 results within Healthcare Facilities industry 24 other companies have achieved higher Revenue growth. While Progyny Inc ' s Revenue increase of 9.08% ranks overall at the positon no. 2316 in the third quarter 2026.


PGNY Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 9.08 %
2nd Quarter June 5.58 %
1st Quarter March 1.32 %
FY   -

Financial Statements
Progyny Inc 's third quarter 2026 Revenue $ 341.25 millions PGNY's Income Statement
Progyny Inc 's third quarter 2025 Revenue $ 312.84 millions Quarterly PGNY's Income Statement


PGNY Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -2.64 %
2nd Quarter June 6.84 %
1st Quarter March 2.56 %
FY (Year on Year)   -


Back to PGNY Growth rate Comparisons >> Back to PGNY Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #25
Healthcare Sector #337
Overall #2316

Revenue Y/Y Growth Statistics
High Average Low
233.63 % 48.75 % -9.18 %
(Dec 31 2020)   (Jun 30 2020)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry #25
Healthcare Sector #337
Overall #2316
Revenue Y/Y Growth Statistics
High Average Low
233.63 % 48.75 % -9.18 %
(Dec 31 2020)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Progyny Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
61.71 % 9.36 % -20.26 %
(Mar 31 2019)  


PGNY's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Progyny Inc disclosed fall in Revenue from the second quarter by -2.64% to $ 341.25 millions, from $ 350.51 millions achived in the previous reporting period.

But that's not important problem, as Progyny Inc 's Revenue generally seem to plunge in this quarter.

Within Healthcare Facilities industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Progyny Inc 's Revenue growth quarter on quarter, overall rank is 985.


Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #9
Healthcare Sector #149
Overall #985
Revenue Q/Q Growth Company Ranking
Within: No.
Healthcare Facilities Industry #9
Healthcare Sector #149
Overall #985
Revenue Q/Q Growth Statistics
High Average Low
61.71 % 9.36 % -20.26 %
(Mar 31 2019)  


PGNY's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Progyny Inc disclosed fall in Revenue from the second quarter by -2.64% to $ 341.25 millions, from $ 350.51 millions achived in the previous reporting period.

But that's not important problem, as Progyny Inc 's Revenue generally seem to plunge in this quarter.

Within Healthcare Facilities industry 8 other companies have achieved higher Revenue quarter on quarter growth. While Progyny Inc 's Revenue growth quarter on quarter, overall rank is 985.


Progyny Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,311.30
Y / Y Revenue Growth (TTM) 5.63 %
Year on Year Revenue Growth Overall Ranking # 1487
Seqeuential Revenue Change (TTM) 1.43 %
Seq. Revenue Growth (TTM) Overall Ranking # 2379


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Progyny Inc 's cumulative twelve months Revenue were $ 1,311 millions, company would post below average annual Revenue growth of 1.43% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Progyny Inc 's Revenue growth from the 350.51% growth in Mar 31 2026.

In the Healthcare sector 250 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1265 to 1487.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 25
Healthcare Sector # 251
Overall # 1487

Revenue TTM Y/Y Growth Statistics
High Average Low
233.63 %
 48.75 %
-9.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 343
S&P 500 # 2379
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Progyny Inc 's cumulative twelve months Revenue were $ 1,311 millions, company would post below average annual Revenue growth of -9.18% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Progyny Inc 's Revenue growth from the 350.51% growth in Mar 31 2026.

In the Healthcare sector 250 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1265 to 1487.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Healthcare Facilities Industry # 25
Healthcare Sector # 251
Overall # 1487

Revenue TTM Y/Y Growth Statistics
High Average Low
233.63 %
48.75 %
-9.18 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 343
S&P 500 # 2379




Other Revenue Growth
Healthcare Facilities Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PGNY's Revenue Growth Ratio versus Healthcare Facilities Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions


About Progyny Inc Revenue Growth Rates (PGNY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Progyny Inc (CIK 1551306).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001551306-26-000170
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Progyny Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.